Download Zipped Introduced WordPerfect HB0268.ZIP
[Status][Bill Documents][Fiscal Note][Bills Directory]

H.B. 268

             1     

DRUG UTILIZATION REVIEW COMMITTEE

             2     
AMENDMENTS

             3     
2005 GENERAL SESSION

             4     
STATE OF UTAH

             5     
Sponsor: Rebecca D. Lockhart

             6     
             7      LONG TITLE
             8      General Description:
             9          This bill amends the Health Code to require public notice and comment period for
             10      hearings held by the Drug Utilization Review Board.
             11      Highlighted Provisions:
             12          This bill:
             13          .    requires 30 days advance public notice of a hearing held by the Drug Utilization
             14      Review Board; and
             15          .    requires the board to consider comments submitted by interested parties.
             16      Monies Appropriated in this Bill:
             17          None
             18      Other Special Clauses:
             19          None
             20      Utah Code Sections Affected:
             21      AMENDS:
             22          26-18-105, as enacted by Chapter 273, Laws of Utah 1992
             23     
             24      Be it enacted by the Legislature of the state of Utah:
             25          Section 1. Section 26-18-105 is amended to read:
             26           26-18-105. Drug prior approval program.
             27          Any drug prior approval program approved or implemented by the board shall meet the



             28      following conditions:
             29          (1) no drug may be placed on prior approval for other than medical reasons;
             30          (2) the board shall hold a public hearing at least 90 days prior to placing a drug on prior
             31      approval;
             32          (3) notwithstanding the provisions of Section 52-4-6 , the board shall provide not less
             33      than 30 days notice to the public before holding a public hearing under Subsection (2);
             34          (4) the board shall consider written and oral comments submitted by interested parties
             35      prior to or during the hearing held in accordance with Subsection (2);
             36          [(3)] (5) the board shall provide evidence that placing a drug class on prior approval
             37      will not impede quality of recipient care and that the drug class is subject to clinical abuse or
             38      misuse;
             39          [(4)] (6) no later than nine months after any drug class is placed on prior approval, it
             40      shall be reconsidered in a public hearing with notice as provided in Subsection (3);
             41          [(5)] (7) the program shall provide either telephone or fax approval or denial at least
             42      Monday through Friday, within 24 hours after receipt of the prior approval request;
             43          [(6)] (8) the program shall provide for the dispensing of at least a 72-hour supply of the
             44      drug in an emergency situation or on weekends;
             45          [(7)] (9) the program may not be applied to prevent acceptable medical use for
             46      appropriate off-label indications; and
             47          [(8)] (10) any drug class placed on prior approval shall receive a majority vote by the
             48      board for that placement, after meeting the requirements described in Subsections (1) through
             49      [(7)] (10).




Legislative Review Note
    as of 1-13-05 8:46 AM


Based on a limited legal review, this legislation has not been determined to have a high
probability of being held unconstitutional.

Office of Legislative Research and General Counsel


[Bill Documents][Bills Directory]